Here are the latest quarterly results of PFIZER. For more details, see the PFIZER financial fact sheet and PFIZER share price and chart. For a sector overview, read our pharmaceuticals sector report.
No. of Mths Qtr. Ending |
3
Jun-20* |
3
Sep-20* |
3
Dec-20* |
3
Mar-21* |
3
Jun-21* |
3
Sep-21* |
3
Dec-21* |
3
Mar-22* |
8-Qtr Chart Click to enlarge |
|
---|---|---|---|---|---|---|---|---|---|---|
Net Sales | Rs m | 5,149 | 5,954 | 5,935 | 5,348 | 7,492 | 6,363 | 6,759 | 5,497 | |
Other income | Rs m | 172 | 122 | 146 | 372 | 122 | 150 | 183 | 171 | |
Turnover | Rs m | 5,321 | 6,076 | 6,081 | 5,720 | 7,614 | 6,513 | 6,942 | 5,668 | |
Expenses | Rs m | 3,286 | 3,921 | 3,967 | 4,090 | 4,634 | 4,469 | 4,807 | 3,842 | |
Gross profit | Rs m | 1,863 | 2,033 | 1,968 | 1,257 | 2,857 | 1,894 | 1,952 | 1,655 | |
Depreciation | Rs m | 271 | 277 | 272 | 273 | 270 | 272 | 272 | 336 | |
Interest | Rs m | 30 | 47 | 39 | 35 | 23 | 22 | 22 | 39 | |
Profit before tax | Rs m | 1,733 | 1,830 | 1,803 | 1,321 | 2,687 | 1,750 | 1,841 | 1,451 | |
Tax | Rs m | 489 | 517 | 390 | 315 | 688 | 320 | 402 | 193 | |
Profit after tax | Rs m | 1,245 | 1,314 | 1,412 | 1,006 | 1,999 | 1,430 | 1,439 | 1,258 | |
Gross profit margin | % | 36.2 | 34.1 | 33.2 | 23.5 | 38.1 | 29.8 | 28.9 | 30.1 | |
Effective tax rate | % | 28.2 | 28.2 | 21.6 | 23.9 | 25.6 | 18.3 | 21.8 | 13.3 | |
Net profit margin | % | 24.2 | 22.1 | 23.8 | 18.8 | 26.7 | 22.5 | 21.3 | 22.9 | |
Diluted EPS | Rs | 27.2 | 28.7 | 30.9 | 22.0 | 43.7 | 31.2 | 31.5 | 27.5 | |
Diluted EPS (TTM) | Rs | 113.8 | 108.8 | 109.3 | 108.8 | 125.3 | 127.8 | 128.4 | 133.9 | |
![]() |
After opening the day deep in the red, Indian share markets slowly recovered most of their losses and ended on a flat note.
It came as a surprise to everyone when Sun Pharma reported a consolidated net loss in Q4 instead of a profit.
Here's why Divi's Lab's stock fell over 10% in two days.
For full year, profit figures stood at Rs 29.6 bn as against Rs 19.8 bn for the previous year, reflecting a growth of 49%.
During Q4, there were many changes to the products forming part of Dr Reddy's generics and proprietary products segments.
The pandemic has opened up new opportunities for the Indian pharmaceutical sector. Which company is set to benefit from it?
More Views on NewsThis aspect of investing has a very high weightage on your overall returns, but often gets ignored when winning stories are written.
Why this may not be the best time to buy smallcaps.
The good side of a market correction? Investors get consistent compounding stocks at a discount.
These value stocks have the potential to deliver good returns in the long run. Watch out for them.
Global markets have become volatile, sending chills through the crude oil market.
More